New Italian VC’s first play is Spanish biotech chasing notoriously difficult target 

Recently launched European investment vehicle AurorA Science has placed its first marker on a company going after one of life sciences’ most infamous oncogene targets: MYC.

AurorA Science led Barcelona-based Peptomyc S.L.’s €11.4 million ($13.8 million) series B round, which had participation from existing investors Alta Life Sciences, HealthEquity, the Center for the Development of Industrial Technology (CDTI) and undisclosed angel investors...